| Program | Pre-IND | Phase 1 | Phase 2 | Status |
|---|
|
| Elevate Cusatuzumab in combination with venetoclax and azacitidine in elderly patients with newly diagnosed AML | | On-Going
interim efficacy and safety data reported
|
| Culminate Cusatuzumab in combination with azacitidine in elderly patients with newly diagnosed AML | | On-Going
interim efficacy and safety data reported |
| Risk Stratified Phase 2 Study Randomized Phase 2 trial of cusatuzumab + azacitidine + venetoclax vs venetoclax + azacitidine in a risk-stratified patient population of elderly, newly diagnosed AML | | Currently enrolling |
| Pre-IND | Phase 1 | Phase 2 |
| Elevate Cusatuzumab in combination with venetoclax and azacitidine in elderly patients with newly diagnosed AML |
|
Status: On-Going
interim efficacy and safety data reported
|
| Culminate Cusatuzumab in combination with azacitidine in elderly patients with newly diagnosed AML |
|
Status: On-Going
interim efficacy and safety data reported |
| Risk Stratified Phase 2 Study Randomized Phase 2 trial of cusatuzumab + azacitidine + venetoclax vs venetoclax + azacitidine in a risk-stratified patient population of elderly, newly diagnosed AML |
|
Status: Currently enrolling |
